IJHSR

International Journal of Health Sciences and Research

| Home | Current Issue | Archive | Instructions to Authors |

Original Research Article

Year: 2020 | Month: April | Volume: 10 | Issue: 4 | Pages: 90-94

Evaluating the Anticancer Activity of Homoeopathic Preparation of Asterias rubens in Breast Cancer Cell Line on the Basis of Similia Principle

Ekta Gupta1, Ruchika Kaul-Ghanekar2, SS Manhas3, Arun Bhargav4

1Post Graduate Scholar, 3Associate Professor,
Department of Organon of Medicine with Homoeopathic Philosophy, Bharati Vidyapeeth (Deemed to be University) Homoeopathic Medical College and Hospital, Katra-Dhankawadi, Pune, Maharashtra, India.
2Interactive Research School for Health, Affairs (IRSHA), Bharati Vidyapeeth, Pune-Satara Road, Pune, Maharashtra, India.
4Principal, Bharati Vidyapeeth (Deemed to be University) Homoeopathic Medical college and Hospital, Katra-Dhankawadi, Pune, Maharashtra, India.

Corresponding Author: Ekta Gupta

ABSTRACT

Breast cancer is the second leading cause of cancer death in woman and ranks as the first leading cause of death in India. In its treatment several measures and recommendation are considered. Homoeopathic medicines are the one of the part of complementary and alternative medicines are used for the treatment of cancer. The objective of the study is to evaluate the anticancer activity of homoeopathic preparations of Asterias rubens on the basis of similia principle. We conducted an in vitro study using MTT assay to determine the effect of ultra diluted homoeopathic remedy against two human breast adenocarcinoma cell lines(MCF-7 and MDA-MD-231), frequently used for the breast cancer treatment, by testing the viability of breast cancer (MCF-7 and MDA-MD-231) cell line, with various attenuations of Asterias rubens at 24 hrs. Multiple comparisons between tested reagents at different concentrations confirmed significance of the said results. At dilution of 1:25 6CH and 30CH potency shown superior activity on MCF-7 and no such significant changes on MDA-MD-231 at any dilutions as it lacks estrogen receptor(ER) and progesterone receptor (PR) expression, as well as HER2 (human epidermal growth factor receptor2) so being a triple negative breast cancer it is an aggressive form of breast cancer with limited treatment options. However, further potency need to be tested. These preliminary significant results warrant further in vitro and in vivo studies to evaluate the potential of Asterias rubens a medicine to treat breast cancer.

Key words: Asterias rubens, Anticancer activity, Breast cancer cell line, Similia Principle

[PDF Full Text]